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ABSTRACT
Important questions about health care are often addressed by studying health care
utilization. Utilization data have several characteristics that make them a chal-
lenge to analyze. In this paper we discuss sources of information, the statistical
properties of utilization data, common analytic methods including the two-part
model, and some newly available statistical methods including the generalized
linear model. We also address issues of study design and new methods for dealing
with censored data. Examples are presented.
INTRODUCTION
Important questions about health care are often addressed by analyzing health
care utilization data. A finding that people with lower income or who live
in certain areas of the country use fewer services can indicate problems with
access to care. If patterns of use are found to vary by insurance plan, this
may suggest positive or negative properties of managed care. Studies that show
high variation among geographic areas in rates at which a surgical procedure is
performed suggest that residents in some of those areas are not receiving optimal
care. Another important area of research is prediction of total health care costs
125
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for a group of people for a year, so that providers can be paid appropriate rates
for caring for those people.
Multiple regression methods are used extensively to adjust analyses for
important patient characteristics or to predict future utilization for individu-
als (1, 13, 14, 20, 31, 33, 34; MC Hornbrook, RT Meenan, DJ Bachman, MC
O’Keefe Rosetti, MJ Goodman, et al, submitted for publication). Utilization
data have several characteristics that make them a challenge to analyze. Over the
years general approaches for analysis have evolved, and some new approaches
are now possible because of advances in analytic methods and software. In
this paper we discuss sources of data, the statistical properties of utilization
data, common analytic methods, the use of newly available computing meth-
ods, study design, and methods for dealing with censored data. We use data
from an evaluation of Washington State’s Basic Health Plan to illustrate these
methods (7, 24).
SOURCES AND QUALITY OF DATA
Fifty years ago, patient utilization data had to be obtained directly from pa-
tients or by abstracting medical records. Such data are expensive to obtain
and of questionable quality. In health services research today, such data are
used primarily to supplement information obtained from large administrative
databases. Examples of administrative databases include the national Medi-
care and Medicaid databases as well as some state registries and claims files
for privately insured patients or members of a particular health facility. Some
databases have been created especially for health services research.
Data from the Medicare program, run by the Health Care Financing Authority
(HCFA), are confidentiality-protected, research-quality, longitudinally linked,
person-level records that track virtually all elderly US citizens from their 65th
birthday onwards, through geographical moves and changes in providers, until
death. (About 10% of Medicare enrollees are younger, disabled persons, who
are tracked from their time of certification.) Available data include the types
and amounts of health services used (e.g. hospitalizations, office visits, home
health care, surgeries, and diagnostic tests), the medical problems being treated
(diagnoses), provider characteristics (site of service and physician training),
and charges. Information on long-term care services and outpatient prescription
drugs, not covered by HCFA, is not available. Data for capitated managed care
systems [health maintenance organizations (HMOs)] are currently incomplete,
but should be adequate for analysis by the year 2000. In addition, the Medicare
Current Beneficiary Survey collects longitudinal data on all types of health
insurance coverage, on health status, and on sources of payment for all health
care utilization for Medicare beneficiaries.
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Data are also available about state Medicaid programs, which offer health
coverage to low-income persons, most often women with children. These data
are of varying quality and, because each state administers its own program, eli-
gibility requirements are state specific and change over time. In addition, people
move on and off the system as their eligibility changes, and the same person may
appear under different identification numbers. More than 30 states currently
submit person-level Medicaid data to HCFA, which monitors their quality and
constructs and maintains standardized Medicaid research files known as the
Medicaid Statistical Information System (MSIS).
Data about privately insured populations in the United States, usually under
age 65, have been used extensively in health service research. Such data are
reasonably complete but events such as job loss, geographical movement, mar-
riage, divorce, and alternative coverage that becomes available (or is lost) to
a spouse or child can disrupt data continuity. Information on services may be
lost if the service was billed to a different insurance plan. There is often less
information available about dependents than about the contract holder.
The quality of claims data is adequate for many purposes, but it is important
to remember that claims are generated to justify reimbursement rather than to
facilitate research. For example, a bill for tests to rule out cancer may contain a
diagnostic code for “cancer” even if the tests were negative. Few administrative
systems capture outside or “out-of-pocket” utilization, such as purchases of
nonprescription drugs and use of alternative or noncovered services.
Some states maintain public use files of each hospital discharge. These can
be valuable, although the amount of additional information known about a per-
son is usually limited. It often is not possible to identify multiple admissions for
the same person, and in some states only civilian hospitals are included. An ex-
cellent population-based data set, created by the Agency for Health Care Policy
and Research and the National Center for Health Statistics, is the Medical Ex-
penditures Panel Survey (MEPS) (5), which collects data from several sources
to provide a complete picture of the health status and health care utilization of
a random sample of citizens.
Descriptions of methods for collecting and analyzing utilization data may be
found in several references (5, 19, 26).
MEASURES OF UTILIZATION AND COST
Utilization can be measured as the number of services provided to a patient,
such as the number of X rays. More often, however, a variety of procedures
and services are of interest, and some measure of “cost” is assigned to each
service so that resource intensity can be summed over all provided services.
Here we use the word “cost” for simplicity; however, our examples are based
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on billed charges, which differ from the amount paid because of discounts,
deductibles, copayments, and coinsurance. Billed charges do not represent all
of a person’s costs, because patients may have other coverage and typically pay
for many costs out of pocket.
Billed charges rarely represent the cost to the provider of providing a par-
ticular service, because the actual cost of a procedure is difficult to define and
calculate. Some providers use step-down accounting systems that allocate fixed
overhead expenses to particular services. The cost estimate for, say, a mam-
mogram, which results from such a detailed accounting process is appropriate
from the accounting perspective, but it may vary substantially in a short period
of time, owing to changes in the volume of mammograms performed or to
shortfalls in seemingly unrelated parts of the system. Such data must be used
with care in research.
Because pricing systems are likely to vary among providers, investigators
sometimes adjust the charges by a facility’s “cost-to-charge” ratio. Such an
approach assumes that costs are actually known and that the relationship of costs
to charges can be represented very simply. Another approach is to summarize
utilization by counting each unit of care and applying a “relative value” to each
procedure performed (2) instead of using the facility charges. If two providers
treat cases identically but have different charge structures, the relative-value
approach will find the two providers to be equivalent. Depending on the goals
of the analysis, it may be appropriate to study charges, costs, or relative values.
These approaches will not always yield the same results.
DISTRIBUTIONAL PROPERTIES
OF UTILIZATION DATA
Utilization data are generally analyzed by using ordinary least squares regres-
sion, but they do not satisfy the standard assumptions for that method. To illus-
trate these points, we present data from the evaluation of Washington State’s
Basic Health Plan, which provided subsidized health insurance for low-income
residents, starting in 1989 (7, 24). The 6918 subjects in the study were enrolled
in four health plans, 26% in a HMO and 74% in one of three independent-
practice associations (IPA). Subjects were aged 0–65 years (mean 23 years)
and were followed for an average of 22 months (range 1–44 months). The
length of follow-up depended on when the person joined the program relative
to the end of the evaluation period and is probably not related to the person’s
health. During the study period, 79% of subjects used some services, and an-
nualized outpatient costs ranged from 0 to $22,452; the mean annualized cost
was $390, and the standard deviation was $895.
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Model Assumptions
It is tempting to treat the numbers of visits or admissions as count data and
to analyze them by using Poisson models. However, the units counted are not
independent, and such a model will usually underestimate the variance.
Ordinary least squares (OLS) regression that includes hypothesis testing
requires the dependent variable to satisfy normality, homoscedasticity, and
independence assumptions. (More formally, the residual error must satisfy
these assumptions. Since the residuals in utilization data usually have a similar
distribution to the original data, we discuss characteristics of the original data.)
Health care utilization variables are usually not normally distributed, as they
tend to have a mode at zero and a distribution with a long, heavy right tail. The
distribution often looks more like a lognormal than a Poisson distribution, even
when the data are counts. Figure 1 shows the distribution of annualized outpa-
tient costs for 6918 persons, which is heavily skewed to the right. Costs above
$3000 were truncated at $3000 to make the graph easier to read. The average
cost was $390, with a standard deviation of $895. Total costs are more variable
than outpatient costs because of the relative rarity and high cost of hospital care.
Figure 1 Distribution of annualized outpatient costs.
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Counts of visits, admissions, inpatient days, laboratory procedures, and X rays
also have distributions with many zeroes and a long right tail.
A second assumption of least squares regression is homoscedasticity, i.e.
that the variance is the same for any fixed combination of the covariates. When
we grouped the subjects in our example into 132 categories by age and sex,
there were substantial differences in variance among the subgroups. There was
a strong relationship between mean and standard deviation in the subgroups,
which can be characterized as approximately¾ D 0:6 „1:1. That is, the standard
deviation increases approximately as the mean. This relationship has been noted
elsewhere (3, 6; DK Blough & SD Ramsey, submitted for publication). In
the Poisson distribution, in contrast, the standard deviation increases with the
square root of the mean; in the normal distribution, the mean and variance are
independent.
A third assumption of least squares regression is that the observations are
independent. Utilization data can fail to be independent for several reasons.
There may be multiple hospitalizations for the same patient. Study subjects may
be clustered within families or use the same doctors or hospitals. Hierarchical
modeling has been used to adjust for clustering (17). Generalized-estimating
equations and random-effects models are also appropriate when the number of
clusters is large (21).
Utilization data are often transformed to the log scale, which usually shortens
the long right tail, lessens heteroscedasticity, and decreases the influence of
outliers. Figure 2 shows the distribution of logarithm of “outpatient cost C1”
(one dollar is added to costs to permit calculating a logarithm for people with
no utilization). The distribution resolves into a spike representing the people
who used no services and a somewhat normal-looking distribution for people
who did use services. Models that analyze these two distributions separately
are discussed below. The shape of the distribution will differ by population; a
healthy insured population will have many nonusers, whereas a population of
sick people will have few.
DESIGN OF STUDIES
Length of Follow-Up
When designing a study, investigators must decide how long to follow the sub-
jects. To address this question, we divided the subjects into groups depending
on the number of months they were followed, and we calculated the standard
deviation of annualized costs for each group. There are at least 50 people in
each group, and the smallest number in the groups with 1–4 months of ex-
perience is 143. Figure 3 is a plot of the standard deviation of annualized
outpatient cost versus the number of months the person was followed. For
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Figure 2 Distribution of log-transformed outpatient costs.
example, the leftmost point shows the standard deviation of annualized cost for
people followed only one month; their annualized cost is thus their observed
cost multiplied by 12. Note that there is very little association between the
length of follow-up and the standard deviation. That is, following people for
more than about 6 months does not reduce the variability in annualized outpa-
tient cost. This phenomenon has been noted elsewhere (6) and is similar when
inpatient and outpatient costs are combined. Power considerations (e.g. for
a study comparing one insurance plan with another) thus do not require long
follow-up; however, most investigators prefer to follow subjects for an integral
number of years, to guard against seasonal trends in utilization.
Adjusting Utilization for Different Lengths of Enrollment
When study subjects are followed for different lengths of time, it is common
to annualize the utilization rates. This may seem risky because a person with
only 1 month of follow-up who had an admission during that month would be
estimated to have 12 admissions per year. Figure 3 shows that the standard
deviation for the annualized cost is fairly independent of the number of months
of follow-up for these subjects, whose length of follow-up depended only on
when they entered the study. If subjects have lower follow-up for reasons related
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Figure 3 Standard deviation of annualized outpatient costs compared with months followed.
to their utilization or health, however, people with low follow-up may be a
biased subset. Ellis & Ash suggest annualizing rates but then weighting persons
based on the number of months they were actually observed (12). If length of
follow-up differs among subjects, it is probably a good idea to include length
of follow-up as a covariate as well, since annualization may not completely
remove the effect of time. For example, new enrollees may have pent-up need,
and short-term enrollees could have higher annualized rates because they have
more use in the first few months. Related issues are described below in the
section on censoring.
Sample Size
In the example above, the standard deviation of annualized cost is about $900.
Based on the usual sample size calculation methods, a study with 80% power to
detect a difference in mean cost of, say, 0.2 standard deviations ($180) would
require about 392 people per group. Even though the “effect size” approach
of Cohen (4) calls a difference of 0.2 standard deviations small, a difference in
cost this large would often be unrealistic to expect. A more reasonable expected
difference of $50 per year would require a sample size of about 5100 people per
group. Cost studies usually require large samples before reasonable differences
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can be detected. If pilot data on standard deviations are not available, the
relationship noted above in which the mean is approximately proportional to
the standard deviation may be useful for sample size calculations.
The cost-effectiveness ratio for an intervention is the difference in mean
costs between the treatment and control groups divided by the difference in
mean effectiveness. Traditionally a cost-effectiveness ratio has been presented
as a single number, with no associated measure of variability. In clinical tri-
als, in which costs and benefits may be estimated for the same individuals,
it is possible to use methods such as the bootstrap to provide a confidence
interval for such a ratio (29). In our example, the standard error for the differ-
ence in mean costs for two groups of size 100 each is about $131; with 1000
people it is about $41. When this variability in the numerator is combined
with the likely high variability of the denominator, it becomes clear that very
large studies may be needed to provide a tight bound on the cost-effectiveness
ratio.
ANALYTIC METHODS FOR UTILIZATION DATA
Adjustment for Patient Characteristics
Most analyses attempt to adjust for patient characteristics before testing hy-
potheses about cost. Age and sex are the most common covariates, because
they are reasonable proxies for a person’s need for services and are nearly always
available. Health status, beliefs, and behaviors are sometimes elicited through
surveys of the subjects. Health status is sometimes inferred from the diag-
nostic codes in a person’s previous utilization (12, 19, 33, 34; MC Hornbrook,
RT Meenan, DJ Bachman, MC O’Keefe Rosetti, MJ Goodman, et al, submitted
for publication). A strong predictor of future utilization is previous utilization,
based on survey or claims data. As in any regression analysis, it is important
not to control for variables in the causal pathway. For example, in comparing
two plans, adjusting for the enrollee’s utilization in the previous year in that
same plan could mask the differences between the plans.
Relationship of Cost to Age and Sex
Most analyses in the literature adjust for age and sex in a very simple way. One
common model is cost D a C b.sex/ C c.age/; this model assumes that the
relationship of age to utilization is linear and that regression lines are parallel
for men and women. An interactive model, cost D a C b.sex/ C c.age/ C
d.age/.sex/, assumes a linear relationship with different slopes for men and
women. Adding a quadratic term, such as cost D a C b.sex/ C c.age/ C
d.age/.sex/ C e.age2/ C f .age2/.sex/, assumes a quadratic relationship that
is different for men and women. The actual relationship of cost to age is not
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Figure 4 Average outpatient costs by age and sex.
simple, as is shown in Figure 4. The curves are nonlinear and differ by sex.
Very young children have high utilization. Males and females have similar
utilization until puberty, at which time women increase their utilization because
of childbearing. Men’s utilization is low until about age 40.
Figure 4 suggests the use of richer age and sex models than those noted above.
The curves in Figure 4 can be fit adequately by using a fifth-order polynomial
in age (different for men and women). Another approach is to use dummy
variables for the various age/sex categories; this requires large sample sizes to
permit good estimates for each age/sex category. If the population of interest
includes only a subgroup of ages, for instance children under age 12 or persons
aged 35–55, simpler models may be appropriate.
Size of R2
In regression analyses of utilization data, the values of R2 are usually on the
order of •20% (27). This should not be surprising considering how difficult it
would be to predict one’s own utilization. The low values of R2 indicate that
we can not predict well for an individual; however, more often we are trying to
predict the average cost for a group of individuals, and regression equations can
often do this quite satisfactorily. Newhouse et al used theoretical and empirical
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arguments to estimate that the maximum possible R2 is about 48% for outpatient
expenditures and 15% for total costs (28).
One-Part Versus Two-Part Model
In analyzing utilization data, the investigator must decide whether to use a
one-part or two-part model and on what scale to model the data.
A one-part model is fit to the data for all people, despite whether they used
any services. The dependent variable could be cost or some transformation such
as log (cost C 1). The one-part model is attractive because of its simplicity,
but Figures 1 and 2 demonstrate that the data do not have the usually assumed
distribution. It is also possible to model costs as having a Poisson, gamma, or
negative-binomial distribution. All of these distributions allow for zeroes and
for long right tails.
A conceptually attractive way to address the concentration of zero values is
a two-part model (10), in which one equation predicts the probability that a
person has any use and a second equation predicts the level of use (usually on
the log scale) for users only. The expected level of use for an individual is then
calculated by multiplying these two estimates together. (This framework has
been extended to a four-part model, in which the probability of hospital use is
estimated among all users and then the costs for users who were hospitalized
and for those who were not are estimated separately.)
Two-part models are attractive because the data then tend to conform to the
analytic assumptions (see Figure 2) and also because they provide insight into
the utilization process. The decision to have any use at all is most likely made
by the person and so is related primarily to personal characteristics, whereas
the cost per user may be more related to characteristics of the health care
system.
Analysis on the Log Scale
We have noted that utilization data are usually non-normal, right-skewed, and
heteroscedastic, with variance that increases with the mean. These features do
not necessarily cause problems. If the data set is very large, OLS regression on
the untransformed data (including the zeros) will provide unbiased estimates
of the regression parameters. The standard errors of regression coefficients
may be too small, giving overly significant hypothesis tests; however, in the
large data sets often available, significant effects are usually so strong that dou-
bling or tripling the standard error would have little affect on the conclusions
(12).
Utilization data have been transformed in various ways to improve their dis-
tribution, including logarithmic and square root transformations. It is difficult
to interpret the coefficients of a square root equation, and both transformations
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cause problems if it is necessary to report results on the original dollar scale,
because the estimates will be biased.
Analysis of utilization data on the log scale is attractive for the statistical rea-
sons mentioned above. There are also conceptual considerations about whether
the relationships being examined are most likely to be additive or multiplicative.
For example, suppose costs for a healthy man are $200 per year, for a healthy
woman are $300, and for a sick man are $2000. Would we expect the cost for
a sick woman to be $300 ¡ $200 D $100 more than a sick man (therefore
$2100), or would she cost proportionately more (300=200£ 2000 D $3000/?
If the latter (multiplicative) model is felt to be more realistic, then the log scale is
appropriate, because the regression coefficients can be exponentiated to provide
estimated ratios of costs (or percentage increases in costs for females compared
with males).
There are two ways to analyze the data on the log scale. The first is to analyze
the logarithm of cost (for users only or for all subjects after adding some con-
stant) by using OLS. The second is to choose an analytic model that incorporates
the logarithmic scale. The generalized linear model permits such an analysis
(25). The user chooses a link function that connects the mean and the covariates
(such as log„ D fiC flX), and a variance function (such as ¾ 2 D „2) and fits a
model that has these properties. This link and variance function have been found
appropriate for utilization data (3; DK Blough & SD Ramsey, submitted for pub-
lication). The gamma distribution has this form. The lognormal model also has
this form, although it can not be fit as a generalized linear model. Many statistical
software packages, such as SAS, S+, and STATA, can be used to fit these models.
Other Models
Several authors (11, 23, 32) have advocated the use of the Cox proportional
hazards model in cost analysis. Cox regression is semiparametric in that the
underlying distribution is arbitrary and unspecified, which is attractive because
the distribution of costs is skewed and difficult to parameterize. This approach
to analyzing costs is valid if the data are not censored (see section on censoring,
below). Unfortunately the regression coefficients in the Cox model pertain to
the hazard ratio, which makes them quite difficult to interpret in the context
of medical costs. Rather than referring to a difference in means or a ratio of
costs, the regression coefficients refer to the relationship of the cumulative
distributions. For example, if FEMALE was a binary variable in the regression
equation and the coefficient of FEMALE was 1.2, this would mean that the
proportion of females with costs above “x” would be equal to the proportion of
males with costs above “x,” raised to the e1.2 power (for all values of x). We do
not use the Cox model in this article.
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Example
We analyzed a random 50% of the annualized outpatient data (n D 3143) to
illustrate some of these points. The variable of interest is annualized outpatient
charges or its logarithm. We fit the dependent variable as a quadratic in age,
different for males and females. (This was done only for simplicity of the
example, because Figure 2 suggests a more complex relationship with age and
sex.) We also included the dummy variable IPA (versus HMO), MONTHS
(number of months the person was followed), FAMSIZE (number of people in
family), and NCHRONIC (number of chronic conditions).
ONE-PART MODEL The top three lines of Table 1 are regression coefficients
and significance levels from three one-part models. (Age and sex are not
shown). The first model used cost in dollars as the dependent variable with
OLS and achieved R2 D 0:07. The second used OLS to analyze log (costC 1),
with R2 D 0:18. (These values, from models on different scales, are not com-
parable.) The third fit a gamma distribution to the data by using a log link. The
first line shows that enrollees in the IPA averaged $217 more than those in the
HMO, that annualized costs increased $3.80 for each month the person had
been enrolled, that costs decreased $17 for each additional family member (not
significant), and that costs increased $89 for each chronic disease.
Lines 2 and 3 summarize analyses on the log scale and can be interpreted by
exponentiating the regression coefficient. For IPA, e0:52 D 1:7, which means
that, on average, costs in the IPA were 70% higher than in the HMO. The
statistical significance of the coefficients in the two models on the log scale is
Table 1 Selected coefficients from regression models⁄
IPA Months Famsize NCHRONIC
One-part models
$ 217⁄ 3.8⁄ ¡17.0 89.3⁄
Log-$ 0.519⁄ 0.058⁄ ¡0.029 0.346⁄
Log-gamma 0.609⁄ 0.011⁄ ¡0.042⁄ 0.214⁄
Two-part models
Part 1
Logistic 0.118 0.083⁄ 0.028 0.351⁄
Part 2
$ 258⁄ ¡1.32 ¡24.8⁄ 83.1⁄
Log $ 0.528⁄ 0.001 ¡0.069⁄ 0.178⁄
Gamma 0.604⁄ ¡.004 ¡0.047⁄ 0.167⁄
⁄
, P < 0.05.
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similar to that on the dollar scale, except for FAMSIZE. Signs of the coefficients
were the same in all three models.
TWO-PART MODEL, PART 1 The first part of the two-part model (the probability
of having any use) is usually modeled by using logistic or probit regression. If
the number of months the subject is observed is not the same for all subjects, it
is important to control for length of enrollment (MONTHS) in the regression,
perhaps by using length of enrollment or its logarithm as a covariate. The fourth
line of Table 1 shows that odds of having any use were significantly related to
MONTHS and NCHRONIC, but not to IPA or family size. Note that, in this
situation, having utilization is not a “rare” event, and thus the odds ratio cannot
be interpreted as a relative risk.
TWO-PART MODEL, PART 2 The bottom part of Table 1 shows the regression
equations for part two of the two-part model (for users only). The first model
uses OLS to estimate cost in dollars. IPA, NCHRONIC, and FAMSIZE are
highly significant, and people who used services in an IPA spend about $258
per year more than those in an HMO. The final two analyses used a lognormal
model and a gamma distribution with a log link, respectively. In both models
MONTHS was not statistically significant, but the other three variables were.
Exponentiating the coefficient for IPA, we find that use is higher in the IPAs
than in the HMO by a factor of 1.65 or 1.73 in the two models.
GOODNESS OF FIT The fit of the models to the data can be examined somewhat
by examining the “deviance” for the log normal and log gamma models, which
is equivalent to the residual sum of squares in least squares and has a somewhat
different definition for the gamma model (25). The deviances for the one-part
model were 13,156 for the log normal and 33,197 for the gamma model. For
part 2 of the two-part model, the deviances were 2936 for log normal and 2997
for the gamma. Because better models have smaller deviances, the gamma
distribution fits the data better than the log normal distribution in the one-part
model.
HYPOTHESIS TESTING AND PARAMETER ESTIMATION The one-part models in
Table 1 all show that the IPA has significantly higher costs. For a two-part
model, two hypotheses can be tested. The logistic regression equation showed
that the relative odds of having any use were not significantly different in the
IPA and HMO. Results for the second part of the model from Table 1 all show
that cost for the users is considerably higher for IPA enrollees. Thus, both the
one-part and the two-part models found that people in the IPA cost more than
those in the HMO. The two-part model provides the additional insight that the
enrollees in the two groups were equally likely to use services and that the
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difference was caused by higher costs in the IPA by those who have services,
which is most likely a system effect. This finding for IPAs and HMOs has been
noted elsewhere (8).
ESTIMATING COST FOR AN INDIVIDUAL For the one-part dollar-scale model,
the estimated cost for an individual is simply his regression estimate. For
the one-part models involving log transformations, however, the regression
equation predicts log dollars rather than dollars. Exponentiation of a person’s
estimated log cost provides an estimate of the median cost (geometric mean
cost), rather than the arithmetic mean cost, for people with the same set of
covariates. To understand this relationship, consider a cost data set with 5
observations: $1, $10, $100, $1000, and $10,000. Mean cost is $2,222 and
median cost is $100. Log cost (base ten) would have the values 0, 1, 2, 3,
and 4. The mean log cost is 2.0; 102 D $100, which is considerably below
the mean cost. This will be true whenever the original data have a long right
tail. However, if the log transformation succeeded in making the transformed
data symmetric, then the mean of the logged data is approximately equal to its
median, and the median of the log is the log of the median. For example, the
mean (and median) log cost is 2, and 102 D 100, which is the median cost.
Because the mean and median cost are usually quite different, a factor is
needed to correct for the retransformation bias. There are two commonly used
factors. The first assumes that the data actually have a log normal distribution
and is calculated as exp[.1¡ R2/s2LOG COST=2]. The second is a nonparametric
approach called the Duan Smear, which is calculated as [P exp.ei/]=N, where
ei is the ith residual of the regression on the log scale. For the examples in
Table 1, for the one-part model the lognormal factor was 10.6, and the Duan
factor was 5.0. For the two-part models, the lognormal factor was 1.91 and
the Duan factor was 1.96. The two factors agreed better for the 2-part model
because the lognormal assumption was more nearly met. The equation from
the gamma model must be retransformed to the log scale, but does not have a
retransformation bias because it was modeled on the dollar scale.
For the two-part model, a person’s estimated cost is his probability of hav-
ing any use multiplied by the expected cost conditional on being a user. The
probability of having any use is estimated from the logistic regression equation
(Table 2). The expected cost, given some use, is estimated by exponentiat-
ing the part 2 estimate and multiplying it by the appropriate retransformation
factor.
ACCURACY OF PREDICTION The regression equations of Table 1 were esti-
mated from a random 50% of the data. We then used these regression equations
to estimate cost for the remaining subset. Table 2 shows two summary measures
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Table 2 Root mean square error and mean absolute error in
training and validation sample for different models
Model Dist’n Bias term RMSE MAE
One part Normal 808 383
Lognormal Lognormal 2735 1233
Duan 1395 599
Gamma 819 386
Two part Normal 808 380
Lognormal Lognormal 814 375
Duan 814 378
Gamma 813 381
of fit for the various models, root mean square error (RMSE), and mean ab-
solute error. To calculate RMSE, we calculated each person’s predicted cost,
subtracted the observed cost, squared the difference, took the mean, and then
took the square root. For the mean absolute error (MAE) we calculated the ab-
solute difference between each person’s observed and predicted cost and took
its mean. Table 2 shows that RMSE is high for the one-part log models, using
either retransformation factor. RMSE is fairly similar for the other six models,
and there is no strong difference between the one-part and two-part models.
The relative results are similar for the MAE criterion.
Other authors have compared a variety of statistical models for cost data (23;
G Gifford, W Manning, M Finch, K Edwards, D Knutson & V Weslowski,
submitted for publication; CW Madden, B Mackay, S Skillman, M Ciol &
P Diehr, submitted for publication). Lipscomb et al (23) analyzed models built
on data from 500,000 Medicare patients and assessed the model by using RMSE,
MAE, and also a log score that measures how well the predicted distribution fits
the observed distribution. They recommended against using the untransformed
data. A study utilizing 10,890 disabled persons recommended models based
on untransformed or square root–transformed data rather than log-transformed
data (G Gifford, W Manning, M Finch, K Edwards, D Knutson & V Weslowski,
submitted for publication). Others (CW Madden, B Mackay, S Skillman,
M Ciol & P Diehr, submitted for publication) found little difference in pre-
diction between the one-part and two-part models, using the same data from
disabled persons and also data from 40,000 Washington State employees. Be-
cause the types of populations studied, the predictor variables, the number of
observations, the statistical model, and the measures of “goodness” differed
among these studies, there are many possible explanations for discrepancies in
the findings. There is no current consensus about the best model.
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RECOMMENDATIONS The authors have worked with utilization data for many
years and have used a variety of analytic techniques to address a range of
questions. The method we recommend depends on the primary goal of the
analysis: hypothesis testing to improve understanding of the system, hypothesis
testing to explore the net effect of covariates on costs, or estimation of a person’s
future utilization.
When the goal is understanding the system, a two-part model seems best
because it permits the investigator to distinguish factors that affect the propen-
sity to use any services from factors that affect volume of utilization once the
person has entered the system. The easiest two-part model uses the lognormal
distribution and is solved by using OLS. In the example above, we found that
the IPA and HMO did not differ on the proportion of subjects using services,
but that the cost per user was about twice as high in the IPA as in HMOs.
For understanding the effect of individual covariates on total costs, a one-
part model is most useful because it generates a single regression coefficient
for each variable and so can be interpreted easily. The one-part model on the
dollar scale is easy to interpret but assumes an additive model. The gamma
distribution might be preferred because it is a multiplicative model.
If the goal is prediction of future costs, we recommend a one-part model,
with untransformed cost as the dependent variable, estimated by using least
squares. This model works about as well as the two-part models and does not
require retransformation. It may seem puzzling that the models that are most
similar to the true distribution of the data do not give better predictions, but we
and others have found this to be true in a variety of situations, including the
example in Table 2. Further research and better algorithms may change these
recommendations in the future.
DEATH AND CENSORING
Patients who die shortly after entering a study often use the fewest resources,
whereas those who remain alive for a time but eventually die are among the most
expensive. This suggests a potentially peculiar relationship in which the sickest
subjects have either very high or very low costs—a U-shaped relationship that
should be addressed during modeling. Depending on the goals of the analysis,
a person who dies may not present a problem, because all of his utilization is
known. Calculation of annualized rates can be a problem, however, because
there is usually high utilization in the last year of life.
Censoring is an issue in estimating the average lifetime cost for treating a
particular disease (or similarly the cost until cure, or the cost in a 12-month
period). Most often, the complete costs for some subjects are not fully observed
because the subjects are lost to follow-up or because they are still alive (or not
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cured or discharged or have not been enrolled for 12 months) at the time of data
analysis. In the terminology of survival analysis, the lifetime costs for such
subjects are censored. The estimated cost will be too low if one analyzes all
the available cost data. Alternatively, calculating costs for only the uncensored
subjects is likely to give too much emphasis to subjects who died early, because
people who survive for a longer time are more likely to be censored.
Some investigators have applied standard survival analysis methods such as
Kaplan-Meier estimators, log rank tests, and Cox regression to the problem of
cost evaluation under censoring, by analyzing censored costs as though they
were censored survival times (11, 16, 18, 30). Unfortunately, this strategy is
generally invalid. The main problem is the requirement in standard survival
analysis that the time of death and the corresponding time of censoring must be
independent. When standard survival analysis methods are applied to censored
costs, the time of death corresponds to the total cost at the time of death, and
the time of censoring corresponds to the total cost at the time of censoring; we
observe the former if the subject is uncensored and observe the latter otherwise.
Unfortunately, the total cost at the time of death is not independent of the total
cost at the time of censoring, even if the time of death and time of censoring are
themselves independent. A subject who has high costs per month will usually
have high total costs at both the time of death and time of censoring, whereas a
subject with low costs per month will tend to have low total costs at both times.
Thus, the total cost at the time of death tends to be positively correlated with
the total cost at the time of censoring. This likely violation of the independent
censoring assumption implies that censored costs should not be analyzed by
standard survival methods.
To minimize the bias induced by censoring, Lin et al (22) propose partitioning
the entire time period of interest into a number of small intervals and then
estimating the average lifetime cost either by the sum of the Kaplan-Meier
estimator for the probability of dying in each interval multiplied by the sample
mean of the total costs for the deaths in that interval or by the sum of the
Kaplan-Meier estimator for the probability of being alive at the start of each
interval multiplied by an appropriate estimator for the average cost over the
interval conditional on surviving to the start of the interval. This approach
has since been addressed by others (15; RD Etzioni, EF Feuer, SD Sullivan,
DY Lin, C Hu & SD Ramsey, submitted for publication).
Another approach is a modification of an estimate for quality-adjusted sur-
vival time (35). The Zhao-Tsiatis estimator applied to costs would be the
sample proportion of those lifetime costs, which are known to be greater than x
dollars, with contributions weighted inversely by the probabilities of inclusion.
These two methods were originally developed to estimate the lifetime cost for
a single group of patients, but can be easily extended for comparing two groups
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of patients. Regression techniques, which would allow one to study simultane-
ously various risk factors on the medical cost, are not currently available.
CONCLUSION
We have presented the traditional methods of analyzing health care utilization
data and pointed out some areas in which new statistical methods are being
applied. We do not expect major analytic improvements to result from applying
different regression models to the data. It is more likely that new research in the
area of censored cost data will yield improved understanding of the problem
and that software will be developed to permit covariates to be incorporated in
the analysis of such data.
Visit the Annual Reviews home page at
http://www.AnnualReviews.org
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